Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.13)
# 3,811
Out of 5,182 analysts
315
Total ratings
27.21%
Success rate
-12.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARTV Artiva Biotherapeutics | Maintains: Buy | $15 → $35 | $10.89 | +221.40% | 3 | May 8, 2026 | |
| TGTX TG Therapeutics | Maintains: Buy | $60 → $70 | $42.86 | +63.32% | 2 | May 6, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Buy | $30 | $19.54 | +53.53% | 1 | Apr 28, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $65 → $50 | $27.79 | +79.92% | 6 | Apr 20, 2026 | |
| INKT MiNK Therapeutics | Reiterates: Buy | $35 | $11.04 | +217.03% | 15 | Apr 1, 2026 | |
| ANAB AnaptysBio | Reiterates: Buy | $66 | $69.30 | -4.76% | 15 | Mar 30, 2026 | |
| ATOS Atossa Therapeutics | Maintains: Buy | $7 → $25 | $5.60 | +346.43% | 15 | Mar 26, 2026 | |
| PPBT Purple Biotech | Maintains: Buy | $34 → $30 | $4.13 | +627.27% | 15 | Mar 13, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $9 → $7 | $4.11 | +70.32% | 3 | Mar 10, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $36 → $38 | $14.90 | +155.03% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $3.51 | +99.43% | 13 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $25.36 | +26.18% | 8 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $49 | $17.89 | +173.90% | 22 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.57 | +473.25% | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $47 | $30.68 | +53.19% | 3 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.98 | +859.60% | 13 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $2.38 | +110.08% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.99 | +1,117.29% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.82 | +502.09% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $4.19 | +854.65% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.43 | +1,760.90% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $0.93 | +2,059.13% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.76 | +268.85% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $7.32 | +3,725.14% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.36 | +238.98% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $3.11 | +864.63% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.19 | +464.26% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $2.72 | +6,613.60% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.39 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.10 | - | 1 | Apr 25, 2024 |
Artiva Biotherapeutics
May 8, 2026
Maintains: Buy
Price Target: $15 → $35
Current: $10.89
Upside: +221.40%
TG Therapeutics
May 6, 2026
Maintains: Buy
Price Target: $60 → $70
Current: $42.86
Upside: +63.32%
First Tracks Biotherapeutics
Apr 28, 2026
Initiates: Buy
Price Target: $30
Current: $19.54
Upside: +53.53%
Agios Pharmaceuticals
Apr 20, 2026
Maintains: Buy
Price Target: $65 → $50
Current: $27.79
Upside: +79.92%
MiNK Therapeutics
Apr 1, 2026
Reiterates: Buy
Price Target: $35
Current: $11.04
Upside: +217.03%
AnaptysBio
Mar 30, 2026
Reiterates: Buy
Price Target: $66
Current: $69.30
Upside: -4.76%
Atossa Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $7 → $25
Current: $5.60
Upside: +346.43%
Purple Biotech
Mar 13, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $4.13
Upside: +627.27%
SAB Biotherapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $4.11
Upside: +70.32%
Olema Pharmaceuticals
Mar 9, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $14.90
Upside: +155.03%
Mar 4, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.51
Upside: +99.43%
Mar 2, 2026
Reiterates: Buy
Price Target: $32
Current: $25.36
Upside: +26.18%
Feb 26, 2026
Maintains: Buy
Price Target: $47 → $49
Current: $17.89
Upside: +173.90%
Feb 17, 2026
Initiates: Buy
Price Target: $9
Current: $1.57
Upside: +473.25%
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $30.68
Upside: +53.19%
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $1.98
Upside: +859.60%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $2.38
Upside: +110.08%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $0.99
Upside: +1,117.29%
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $3.82
Upside: +502.09%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $4.19
Upside: +854.65%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.43
Upside: +1,760.90%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $0.93
Upside: +2,059.13%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $9.76
Upside: +268.85%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $7.32
Upside: +3,725.14%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.36
Upside: +238.98%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $3.11
Upside: +864.63%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $3.19
Upside: +464.26%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $2.72
Upside: +6,613.60%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.39
Upside: -
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $2.10
Upside: -